0001209191-17-061542.txt : 20171117
0001209191-17-061542.hdr.sgml : 20171117
20171117170627
ACCESSION NUMBER: 0001209191-17-061542
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20171116
FILED AS OF DATE: 20171117
DATE AS OF CHANGE: 20171117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NEWMAN MARY
CENTRAL INDEX KEY: 0001679132
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37833
FILM NUMBER: 171211794
MAIL ADDRESS:
STREET 1: C/O AUDENTES THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY ST., SUITE 2650
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Audentes Therapeutics, Inc.
CENTRAL INDEX KEY: 0001628738
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461606174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
BUSINESS PHONE: 415-638-6556
MAIL ADDRESS:
STREET 1: 600 CALIFORNIA ST., 17TH FLOOR
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94108
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-11-16
0
0001628738
Audentes Therapeutics, Inc.
BOLD
0001679132
NEWMAN MARY
C/O AUDENTES THERAPEUTICS, INC.
600 CALIFORNIA STREET, 17TH FLOOR
SAN FRANCISCO
CA
94108
0
1
0
0
SVP, Regulatory Affairs
Common Stock
2017-11-16
4
M
0
5740
2.19
A
5740
D
Common Stock
2017-11-16
4
S
0
5740
26.4866
D
0
D
Common Stock
2017-11-16
4
M
0
4260
2.19
A
4260
D
Common Stock
2017-11-16
4
S
0
4260
27.3104
D
0
D
Stock Option (right to buy)
2.19
2017-11-16
4
M
0
10000
0.00
D
2025-02-04
Common Stock
10000
33817
D
Stock Option (right to buy)
27.39
2017-11-16
4
A
0
50000
0.00
A
2021-11-16
Common Stock
50000
50000
D
This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. The lowest price at which shares were sold was $25.96 and the highest price at which shares were sold was $26.90. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
Represents the weighted average sale price. The lowest price at which shares were sold was $26.97 and the highest price at which shares were sold was $27.51.
The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.
The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date.
/s/ Thomas Soloway as attorney-in-fact for Mary Newman
2017-11-17